Godavari Drugs Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530317
₹120.62
▲ 0.12 (0.10%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
36/100
Weak
Valuation
45/100
Fairly Valued
Momentum
87/100
Bullish

QVM read Momentum-led Quality Weak, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹122 Cr
PE (TTM)
23.4
Industry median 36.1 (152 companies)
Price to Book
1.6
PEG (TTM)
10.7
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
4.9
Free Cash Flow
₹-26 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-20.29%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-7.51%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
4.76%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
44.57%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
17.41%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.31
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
1.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2.28
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
3.97%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
7.42%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.01%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
1.85%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
7.84%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
4.89%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.01)
  • No Return on equity is 15% or more (4.9%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.2% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.1%
Low 118.3000 · High 124.9900
1W return
8.1%
Low 107.6000 · High 130.9000
1M return
23.1%
Low 93.0000 · High 130.9000
52W return
4.9%
Low 93.0000 · High 130.9000
Lifetime High ₹126.1600 (Sept. 28, 2026)
Lifetime Low ₹2.7300 (Jan. 3, 2012)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
119.8
10D
117.1
20D
113.4
50D
107.8
100D
104.1
200D
100.1

Delivery and volume

Day avg. delivery
66.9%
Week avg. delivery
67.0%
Month avg. delivery
76.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

121.30
Pivot
First resistance124.31
Second resistance127.99
Third resistance131.00
First support117.62
Second support114.61
Third support110.93
Day RSI59.7
Day MFI75.0
Day MACD4.41
Day MACD signal3.49

Beta

1M1.81
3M1.46
1Y1.46
3Y0.34

Price change analysis

↑ 23.1%
Over 1 Month
LowHigh
93.00130.90
↑ 4.9%
Over 3 Months
LowHigh
93.00130.90
↑ 4.9%
Over 6 Months
LowHigh
93.00130.90
↑ 4.9%
Over 1 Year
LowHigh
93.00130.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 23.4 (own history: 11.8–23.4)
Sell Zone
Revenue (June 30, 2026)
₹28 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹1.1000

Ranks #136 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter40.23%
  • Mutual funds1.26%
  • Other DII1.48%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 40.23% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 0.99% to 1.26% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
16 Jan 2026 TRADELINK EXIM INDIA PVT LTD Bulk Buy 39,217 98.8800 BSE
26 Aug 2024 MADHUSUDHAN GUNDA Bulk Sell 33,892 112.0000 BSE
26 Aug 2024 MADHUSUDHAN GUNDA Bulk Buy 40,000 106.2000 BSE
15 Jun 2023 PRASHANT SHRIMAL Bulk Sell 41,833 93.5200 BSE
6 Jun 2023 MOHIT JAJU Bulk Buy 70,000 87.9900 BSE
6 Jun 2023 SUSHMA KAKANI Bulk Buy 70,000 88.0000 BSE
6 Jun 2023 PRASHANT SHRIMAL Bulk Sell 155,167 88.0000 BSE
19 Dec 2022 NEERAJ JAIN Bulk Sell 37,900 75.8000 BSE
19 Dec 2022 ARHAM SHARE PRIVATE LIMITED Bulk Buy 40,564 75.8000 BSE
19 Dec 2022 ARHAM SHARE PRIVATE LIMITED Bulk Sell 40,564 74.9300 BSE

All bulk and block deals →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 AGM/EGM Godavari Drugs Ltd - 530317 - Shareholder Meeting / Postal Ballot-Outcome of AGM
21 Sep 2026 Insider Trading / SAST Godavari Drugs Ltd - 530317 - Closure of Trading Window
1 Sep 2026 Corp. Action Godavari Drugs Ltd - 530317 - 38Th AGM To Be Held On 25.09.2026 - Book Closure - 19.09.2026 - 25.09.2026 (Both Days) And Evoting, Cutoff Date.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (17.4%)

Weaknesses

  • Low Return on Equity (4.9%)
  • Thin net profit margin (4.0%)
  • High financial leverage (Debt/Equity 1.01)

Opportunities

Data unavailable.

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Godavari Drugs Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.